iCAD (NASDAQ:ICAD) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

iCAD, Inc. (NASDAQ:ICAD) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.61 and traded as high as $2.06. iCAD shares last traded at $1.96, with a volume of 197,827 shares.

Analysts Set New Price Targets

Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a report on Thursday, November 21st.

iCAD Price Performance

The business’s 50-day moving average price is $1.83 and its 200-day moving average price is $1.61. The firm has a market capitalization of $50.43 million, a PE ratio of -14.62 and a beta of 1.40.

Institutional Investors Weigh In On iCAD

An institutional investor recently bought a new position in iCAD stock. Essex LLC purchased a new stake in iCAD, Inc. (NASDAQ:ICAD) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 137,963 shares of the technology company’s stock, valued at approximately $216,000. Essex LLC owned 0.52% of iCAD as of its most recent SEC filing. 24.61% of the stock is currently owned by institutional investors and hedge funds.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.